Pharma Pioneer

Verve Therapeutics Pauses Gene-Editing Clinical Trial Following Patient's Adverse Reaction

17 May 2024
2 min read

A clinical trial for a gene-editing treatment by Verve Therapeutics, known as VERVE-101, has been halted after a participant experienced severe side effects. The individual, who had received a dosage of 0.45-mg/kg of the drug, showed a significant increase in liver enzyme levels and a decrease in blood platelets, both of which are considered serious. These reactions were linked to the treatment, but they did not lead to any clinical signs of disease and were resolved within a short period.
Despite the quick resolution, a safety board advised a temporary halt in new patient enrollment for the Heart-1 study while Verve investigates. The company has informed the FDA and global health authorities about the incident, and the drug's Investigational New Drug application is still in effect.
The news caused Verve's stock to fall by 31% in pre-market trading. The company's CEO, Sekar Kathiresan, stated that they suspect the delivery system of the drug, a lipid nanoparticle (LNP), is responsible for the observed effects. However, the Heart-1 study has provided strong evidence that VERVE-101 can effectively edit the PCSK9 gene in the liver, leading to a significant reduction in LDL cholesterol levels.
Verve is now focusing on the development of VERVE-102, another gene-editing treatment that targets the same gene but uses a different LNP technology that has shown better tolerance in previous trials. The company is planning to start a new study, Heart-2, in the second quarter of 2024 to evaluate the safety and effectiveness of VERVE-102 in patients with specific cholesterol issues.
The Heart-1 study's findings have confirmed that both VERVE-101 and VERVE-102 can effectively target and disable the PCSK9 gene in the liver, which is associated with high cholesterol levels. The study showed an average reduction of 46% in LDL cholesterol levels. The PCSK9 gene encodes a protein that regulates LDL receptor levels in the liver, and its overexpression can lead to elevated cholesterol levels. Both of Verve's treatments use a combination of messenger RNA and guide RNA to achieve their effects.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Ractigen Commences Phase I Clinical Trial with First Patient Treated for NMIBC Using RAG-01
Pharma Pioneer
2 min read
Ractigen Commences Phase I Clinical Trial with First Patient Treated for NMIBC Using RAG-01
17 May 2024
In a significant medical advancement, Ractigen Therapeutics has initiated its first-ever human clinical trial for RAG-01, a novel small activating RNA (saRNA) treatment for NMIBC.
Read →
Verismo Submits FDA Application for IND Approval of SynKIR™-310 for Treating Recurrent or Refractory B-cell NHL
Pharma Pioneer
2 min read
Verismo Submits FDA Application for IND Approval of SynKIR™-310 for Treating Recurrent or Refractory B-cell NHL
17 May 2024
Verismo Therapeutics, a company specializing in CAR T-cell therapies, is progressing with its second clinical trial using the SynKIR™ platform.
Read →
Preliminary Phase 1/2 Clinical Trial Results for mRNA-3927, a Potential mRNA Treatment for Propionic Acidemia, Featured in Nature Journal
Pharma Pioneer
2 min read
Preliminary Phase 1/2 Clinical Trial Results for mRNA-3927, a Potential mRNA Treatment for Propionic Acidemia, Featured in Nature Journal
17 May 2024
Moderna, a biotechnology company, has reported preliminary results from a phase 1/2 clinical trial for mRNA-3927.
Read →
Achilles Therapeutics Reports Interim Phase I/IIa Results for Clonal Neoantigen T Cells in NSCLC and Melanoma with Enhanced Conditioning
Pharma Pioneer
3 min read
Achilles Therapeutics Reports Interim Phase I/IIa Results for Clonal Neoantigen T Cells in NSCLC and Melanoma with Enhanced Conditioning
17 May 2024
Achilles Therapeutics plc has reported interim Phase I/IIa clinical trial data for clonal neoantigen reactive T cells (cNeT) from the CHIRON study for non-small cell lung cancer (NSCLC) and the THETIS study for malignant melanoma
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.